Literature DB >> 26314314

Death ligands and granulysin: mechanisms of tumor cell death induction and therapeutic opportunities.

Luis Martinez-Lostao1,2, Diego de Miguel1, Sameer Al-Wasaby1, Ana Gallego-Lleyda1, Alberto Anel1.   

Abstract

The immune system plays a key role in cancer immune surveillance to control tumor development. The final goal is recognizing and killing transformed cells and consequently the elimination of the tumor. The main effector cell types exerting cytotoxicity against tumors are natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). Although the mechanism of activation of NK cells and CTLs are quite different, both cell types share common antitumor effector mechanisms of cytotoxicity which lead to induction of cell death of tumor cells by apoptosis. Among these mechanisms are the death ligand- and granulysin-mediated cell deaths. In this review, we summarize the main concepts of these effector cytotoxic mechanisms against cancer cells, how NK cells and CTLs use them to control tumor development and the therapeutic approaches currently developed based on these molecules.

Entities:  

Keywords:  Apo2L/TRAIL; NK cells; cytotoxic T lymphocytes; death ligands; granulysin

Mesh:

Substances:

Year:  2015        PMID: 26314314     DOI: 10.2217/imt.15.56

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  12 in total

1.  Anti-tumoral potential of a human granulysin-based, CEA-targeted cytolytic immunotoxin.

Authors:  Raquel Ibáñez-Pérez; Patricia Guerrero-Ochoa; Sameer Al-Wasaby; Rocío Navarro; Antonio Tapia-Galisteo; Diego De Miguel; Oscar Gonzalo; Blanca Conde; Luis Martínez-Lostao; Ramón Hurtado-Guerrero; Laura Sanz; Alberto Anel
Journal:  Oncoimmunology       Date:  2019-07-22       Impact factor: 8.110

2.  Interferon Gamma Secretion of Adaptive and Innate Immune Cells as a Parameter to Describe Leukaemia-Derived Dendritic-Cell-Mediated Immune Responses in Acute Myeloid Leukaemia in vitro.

Authors:  Lara Kristina Klauer; Olga Schutti; Selda Ugur; Fatemeh Doraneh-Gard; Daniel Christoph Amberger; Nicole Rogers; Doris Krämer; Andreas Rank; Christoph Schmid; Britta Eiz-Vesper; Helga Maria Schmetzer
Journal:  Transfus Med Hemother       Date:  2021-07-07       Impact factor: 3.747

3.  Preclinical Studies of Granulysin-Based Anti-MUC1-Tn Immunotoxins as a New Antitumoral Treatment.

Authors:  Patricia Guerrero-Ochoa; Raquel Ibáñez-Pérez; Germán Berbegal-Pinilla; Diederich Aguilar; Isabel Marzo; Francisco Corzana; Martha Minjárez-Sáenz; Javier Macías-León; Blanca Conde; Javier Raso; Ramón Hurtado-Guerrero; Alberto Anel
Journal:  Biomedicines       Date:  2022-05-24

4.  Expression of Death Receptor 4 Is Positively Regulated by MEK/ERK/AP-1 Signaling and Suppressed upon MEK Inhibition.

Authors:  Weilong Yao; You-Take Oh; Jiusheng Deng; Ping Yue; Liang Deng; Henry Huang; Wei Zhou; Shi-Yong Sun
Journal:  J Biol Chem       Date:  2016-08-30       Impact factor: 5.157

5.  Tumor suppressor BLU promotes TRAIL-induced apoptosis by downregulating NF-κB signaling in nasopharyngeal carcinoma.

Authors:  Jiahui Zhou; Zunnan Huang; Ziyou Wang; Shumin Liu; Alf Grandien; Ingemar Ernberg; Zhiwei He; Xiangning Zhang
Journal:  Oncotarget       Date:  2017-07-04

6.  Differential Effects of Influenza Virus NA, HA Head, and HA Stalk Antibodies on Peripheral Blood Leukocyte Gene Expression during Human Infection.

Authors:  Kathie-Anne Walters; Ruoqing Zhu; Michael Welge; Kelsey Scherler; Jae-Keun Park; Zainab Rahil; Hao Wang; Loretta Auvil; Colleen Bushell; Min Young Lee; David Baxter; Tyler Bristol; Luz Angela Rosas; Adriana Cervantes-Medina; Lindsay Czajkowski; Alison Han; Matthew J Memoli; Jeffery K Taubenberger; John C Kash
Journal:  mBio       Date:  2019-05-14       Impact factor: 7.867

Review 7.  The Role of TRAIL/DRs in the Modulation of Immune Cells and Responses.

Authors:  Duygu Sag; Zeynep Ozge Ayyildiz; Sinem Gunalp; Gerhard Wingender
Journal:  Cancers (Basel)       Date:  2019-09-30       Impact factor: 6.639

8.  Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis.

Authors:  Shuo Zhang; Zhen Chen; Puyu Shi; Songqing Fan; Yong He; Qiming Wang; Yixiang Li; Suresh S Ramalingam; Taofeek K Owonikoko; Shi-Yong Sun
Journal:  Theranostics       Date:  2021-02-15       Impact factor: 11.556

9.  Immunoregulatory Effects of Myeloid-Derived Suppressor Cell Exosomes in Mouse Model of Autoimmune Alopecia Areata.

Authors:  Margot Zöller; Kun Zhao; Natalia Kutlu; Nathalie Bauer; Jan Provaznik; Thilo Hackert; Martina Schnölzer
Journal:  Front Immunol       Date:  2018-06-06       Impact factor: 7.561

10.  Intratumoral heterogeneity and clonal evolution in liver cancer.

Authors:  Bojan Losic; Amanda J Craig; Carlos Villacorta-Martin; Sebastiao N Martins-Filho; Nicholas Akers; Xintong Chen; Mehmet E Ahsen; Johann von Felden; Ismail Labgaa; Delia DʹAvola; Kimaada Allette; Sergio A Lira; Glaucia C Furtado; Teresa Garcia-Lezana; Paula Restrepo; Ashley Stueck; Stephen C Ward; Maria I Fiel; Spiros P Hiotis; Ganesh Gunasekaran; Daniela Sia; Eric E Schadt; Robert Sebra; Myron Schwartz; Josep M Llovet; Swan Thung; Gustavo Stolovitzky; Augusto Villanueva
Journal:  Nat Commun       Date:  2020-01-15       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.